What human pharmaceuticals are identified as significant aquatic risks globally?

The study highlights carbamazepine and ciprofloxacin as two widely detected and regulatory relevant human pharmaceuticals posing aquatic risks. While carbamazepine risks were generally low (AR < 0.1), ciprofloxacin showed much higher aquatic risks, exceeding 1 in 223 out of 449 freshwater ecoregions by 2015.

How have aquatic risks from human pharmaceuticals changed over the past two decades?

Aquatic risks due to exposure to human pharmaceuticals like carbamazepine and ciprofloxacin typically increased 10-20 fold between 1995 and 2015. This significant rise underscores the growing challenge for water purification systems globally, as human consumption and environmental persistence contribute to higher concentrations.

Which pharmaceutical, carbamazepine or ciprofloxacin, presents a higher aquatic risk?

Ciprofloxacin presents a significantly higher aquatic risk compared to carbamazepine. In 2015, ciprofloxacin's Aquatic Risk (AR) exceeded 1 for 223 out of 449 freshwater ecoregions, indicating widespread concern. In contrast, carbamazepine's AR was typically low (<0.1), though some densely populated or arid regions showed higher levels up to 1.1.

How are global aquatic risks of pharmaceuticals like carbamazepine and ciprofloxacin modeled?

Aquatic risks are modeled using a three-step procedure: first, predicting country- and year-specific per capita consumption; second, calculating spatially explicit freshwater concentrations via mass balance models for human, wastewater treatment, and environmental fate; and finally, dividing these concentrations by regulatory limit values derived from toxicity tests to determine ecoregion-specific risks.

What advanced water treatment solutions address pharmaceutical contamination in aquatic environments?

Addressing pharmaceutical contamination requires advanced water treatment technologies, particularly for commercial and industrial applications. AMPAC USA's reverse osmosis (RO) and specialized purification systems are engineered to remove a broad spectrum of contaminants, including complex pharmaceutical compounds, ensuring safe and compliant water for diverse sectors like municipalities and food & beverage. Our 30+ years of field experience confirm the necessity of robust solutions.

Aquatic Risks From Human Pharmaceuticals-modelling Temporal

Q: How have aquatic risks from human pharmaceuticals changed over the past two decades?

Aquatic risks due to exposure to human pharmaceuticals like carbamazepine and ciprofloxacin typically increased 10-20 fold between 1995 and 2015. This significant rise underscores the growing challenge for water purification systems globally, as human consumption and environmental persistence contribute to higher concentrations.

Q: Which pharmaceutical, carbamazepine or ciprofloxacin, presents a higher aquatic risk?

Ciprofloxacin presents a significantly higher aquatic risk compared to carbamazepine. In 2015, ciprofloxacin's Aquatic Risk (AR) exceeded 1 for 223 out of 449 freshwater ecoregions, indicating widespread concern. In contrast, carbamazepine's AR was typically low (<0.1), though some densely populated or arid regions showed higher levels up to 1.1.

Q: How are global aquatic risks of pharmaceuticals like carbamazepine and ciprofloxacin modeled?

Aquatic risks are modeled using a three-step procedure: first, predicting country- and year-specific per capita consumption; second, calculating spatially explicit freshwater concentrations via mass balance models for human, wastewater treatment, and environmental fate; and finally, dividing these concentrations by regulatory limit values derived from toxicity tests to determine ecoregion-specific risks.

Q: What advanced water treatment solutions address pharmaceutical contamination in aquatic environments?

Addressing pharmaceutical contamination requires advanced water treatment technologies, particularly for commercial and industrial applications. AMPAC USA's reverse osmosis (RO) and specialized purification systems are engineered to remove a broad spectrum of contaminants, including complex pharmaceutical compounds, ensuring safe and compliant water for diverse sectors like municipalities and food & beverage. Our 30+ years of field experience confirm the necessity of robust solutions.

\\n

By:Oldenkamp, R (Oldenkamp, Rik)^[ 1,2 ]; Beusen, AHW (Beusen, Arthur H. W.)^[ 3,4 ]; Huijbregts, MAJ (Huijbregts, Mark A. J.)^[ 1,3 ]

\\nView ResearcherID and ORCID\\n\\n

\\n

ENVIRONMENTAL RESEARCH LETTERS

\\n\\n

\\n

Volume: 14

\\n

Issue: 3

\\n\\n

\\n

Article Number: 034003

\\n

DOI: 10.1088/1748-9326/ab0071

\\n

Published: MAR 2019

\\n

Document Type:Article

\\n\\n

\\n

Abstract

\\n

There are pharmaceuticals in water all over the world, but we haven’t had a full picture of the aquatic risk (AR) they pose globally. We’re changing that. We’ve developed a way to estimate ARs for human pharmaceuticals at the freshwater ecoregion level. Here’s how it works: First, we predict how much a country uses per person each year, using a regression model. Next, we figure out exact freshwater concentrations. We do this by combining mass balance models that track where the pharmaceutical goes-in humans, through wastewater treatment plants, and finally into the environment. Last, we take those freshwater concentrations for each ecoregion and divide them by the regulatory limit from toxicity tests. That gives us an ecoregion-specific AR. We used this method to model how ARs for carbamazepine and ciprofloxacin changed from 1995-2015. These are two common, important human pharmaceuticals. Our analysis showed that ARs from these drugs usually jumped 10-20 times over those 20 years. Carbamazepine risks were generally low during this time, with an AR less than 0.1. But some crowded or dry ecoregions saw higher ARs, up to 1.1. Ciprofloxacin risks were much higher. In 2015, 223 out of 449 freshwater ecoregions had ARs greater than 1. When we compared our predictions to actual measurements in ten river basins, carbamazepine concentrations matched up well. However, our model generally underestimated ciprofloxacin concentrations, sometimes by one to two orders of magnitude, when compared to measurements in four river basins. This procedure is a solid first step for evaluating ARs of many human pharmaceuticals globally.

\\nhttp://cel.webofknowledge.com/InboundService.do?customersID=Alerting&smartRedirect=yes&mode=FullRecord&IsProductCode=Yes&product=CEL&Init=Yes&Func=Frame&action=retrieve&SrcApp=Alerting&SrcAuth=Alerting&SID=8APM5GfQaTth5yBsaD9&UT=WOS%3A000459446300001\\n\\n

\\nThe post Aquatic risks from human pharmaceuticals-modelling temporal trends of carbamazepine and ciprofloxacin at the global scale appeared first on Facts About Water.\\n\\nSource: Water Feed